Celcuity Appoints Charles Romp to its Board of Directors

Core Insights - Celcuity Inc. has appointed Charles (Chip) R. Romp to its Board of Directors, bringing over 25 years of experience in the pharmaceutical industry, particularly in oncology [1][2] - Mr. Romp's expertise in commercializing significant oncology drugs is expected to provide valuable insights as Celcuity advances its programs and prepares for the potential approval and launch of gedatolisib later this year [2][3] Company Overview - Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications [3] - The lead therapeutic candidate, gedatolisib, is a potent pan-PI3K and mTORC1/2 inhibitor that blocks the PI3K/AKT/mTOR pathway comprehensively [3] - Celcuity is conducting several clinical trials, including a Phase 3 trial (VIKTORIA-1) for gedatolisib in combination with fulvestrant for HR+/HER2- advanced breast cancer, which has completed enrollment [3] - Another Phase 3 trial (VIKTORIA-2) is currently enrolling patients, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for HR+/HER2- advanced breast cancer [3] Leadership Experience - Mr. Romp is currently the CEO of Secura Bio and previously served as Executive Vice President, Commercial U.S., at Seagen, Inc., overseeing the entire commercial organization [2] - He has a history of managing the growth of key oncology products such as ADCETRIS, PADCEV, TUKYSA, and TIVDAK at Seagen [2] - Prior to Seagen, Mr. Romp held senior sales leadership positions at Genentech, responsible for oncology and immunology products [2]